Evidence map›Paper›PMID 38380580›Full record

ArticleClinical and translational science2024

Using a wearable patch to develop a digital monitoring biomarker of inflammation in response to LPS challenge.

Stefan Avey, Meenakshi Chatterjee, Nikolay V Manyakov, Philip Cooper, Nina Sabins, Kenneth Mosca, Simone Mori, Frédéric Baribaud, Mark Morris, Joseph Lehar and 7 more

Abstract read
In one paragraph

Article in Clinical and translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Stefan AveyJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.ORCID 0000-0003-2768-4337
Meenakshi ChatterjeeJanssen Pharmaceutical Research and Development, Boston, Massachusetts, USA.ORCID 0000-0003-4548-8962
Nikolay V ManyakovJanssen Pharmaceutical Research and Development, Beerse, Belgium.ORCID 0000-0001-9037-1400
Philip CooperJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.
Nina SabinsJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.
Kenneth MoscaJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.
Simone MoriJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.
Frédéric BaribaudJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.ORCID 0009-0006-1484-1881
Mark MorrisJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.ORCID 0009-0009-5221-0783
Joseph LeharJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.
Annemie DeiterenJanssen Pharmaceutical Research and Development, Merksem, Belgium.ORCID 0000-0002-3841-8731
Marta CossuJanssen Pharmaceutical Research and Development, Leiden, The Netherlands.
Sophie SmetsJanssen Pharmaceutical Research and Development, Merksem, Belgium.
Tanja HuizerJanssen Pharmaceutical Research and Development, Leiden, The Netherlands.
Esi Lamousé-SmithJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.ORCID 0000-0002-1067-5795
Kim CampbellJanssen Pharmaceutical Research and Development, Spring House, Pennsylvania, USA.
Ioannis PandisJanssen Pharmaceutical Research and Development, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Remote inflammation monitoring with digital health technologies (DHTs) would provide valuable information for both clinical research and care. Controlled perturbations of the immune system may reveal physiological signatures which could be used to develop a digital biomarker of inflammatory state. In this study, molecular and physiological profiling was performed following an in vivo lipopolysaccharide (LPS) challenge to develop a digital biomarker of inflammation. Ten healthy volunteers received an intravenous LPS challenge and were monitored for 24 h using the VitalConnect VitalPatch (VitalPatch). VitalPatch measurements included heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and skin temperature (TEMP). Conventional episodic inpatient vital signs and serum proteins were measured pre- and post-LPS challenge. The VitalPatch provided vital signs that were comparable to conventional methods for assessing HR, RR, and TEMP. A pronounced increase was observed in HR, RR, and TEMP as well as a decrease in HRV 1-4 h post-LPS challenge. The ordering of participants by magnitude of inflammatory cytokine response 2 h post-LPS challenge was consistent with ordering of participants by change from baseline in vital signs when measured by VitalPatch (r = 0.73) but not when measured by conventional methods (r = -0.04). A machine learning model trained on VitalPatch data predicted change from baseline in inflammatory protein response (R

Indexed as

LipopolysaccharidesWearable Electronic DevicesBiomarkersHumansInflammationVital SignsBiomarkersLipopolysaccharides

Identifiers

PMID38380580
PMCPMC10880037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.